Increased fibrinolysis increases bleeding in orthopedic patients receiving prophylactic fondaparinux

International Journal of Hematology

Volumn 95, Issue 2, 2012, Pages 160-166

  Yoshida, Kakunoshin ^a   Wada, Hideo ^a   Hasegawa, Masahiro ^a   Wakabayashi, Hiroki ^a   Matsumoto, Takeshi ^a   Shimokariya, Yuji ^a   Noma, Katsura ^a   Yamada, Norikazu ^a   Uchida, Atsumasa ^a   Nobori, Tsutomu ^a   Sudo, Akihiro ^a  

^a MIE UNIVERSITY   (Japan)

Author keywords

Bleeding; Deep vein thrombosis (DVT); Fibrinolysis; Fondaparinux; Orthopedic surgery

Indexed keywords

ANTITHROMBIN; BLOOD CLOTTING FACTOR 10A; FIBRIN; FONDAPARINUX; HEMOGLOBIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; ANTICOAGULANT AGENT; BIOLOGICAL MARKER; FIBRIN DEGRADATION PRODUCT; FIBRIN FRAGMENT D; FIBRINOGEN; POLYSACCHARIDE;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CLINICAL ARTICLE; DEEP VEIN THROMBOSIS; FEMALE; FIBRINOLYSIS; HEMOSTASIS; HUMAN; MALE; PROPHYLAXIS; TOTAL HIP PROSTHESIS; TOTAL KNEE REPLACEMENT; BLOOD; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; DRUG ANTAGONISM; DRUG EFFECT; HIP ARTHROPLASTY; KNEE ARTHROPLASTY; METABOLISM; MIDDLE AGED; PHYSIOLOGY; POSTOPERATIVE COMPLICATION; VEIN THROMBOSIS;

AGED; ANTICOAGULANTS; ARTHROPLASTY, REPLACEMENT, HIP; ARTHROPLASTY, REPLACEMENT, KNEE; BIOLOGICAL MARKERS; FACTOR XA; FEMALE; FIBRIN; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOGEN; FIBRINOLYSIS; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; POLYSACCHARIDES; POSTOPERATIVE COMPLICATIONS; VENOUS THROMBOSIS;

EID: 84862682274     PISSN: 09255710     EISSN: 18653774     Source Type: Journal    
DOI: 10.1007/s12185-012-1004-2     Document Type: Article

References (27)

1. Linkins LA, Bates SM, Ginsberg JS, Kearon C. Use of different D-dimer levels to exclude venous thromboembolism depending on clinical pretest probability. J Thromb Haemost. 2004;2:1256-60. (Pubitemid 40186117)
2. Wada H, Kobayashi T, Abe Y, Hatada T, Yamada N, Sudo A, Uchida A, Nobori T. Elevated levels of soluble fibrin or D-dimer indicate high risk of thrombosis. J Thromb Haemost. 2006;4: 1253-8.
3. Wada H, Sakuragawa N, Shiku H. Hemostatic molecular markers before onset of disseminated intravascular coagulation in leukemic patients. Semin Thromb Hemost. 1998;24:293-7. (Pubitemid 28345741)
4. Lehman CM, Wilson LW, Rodgers GM. Analytic validation and clinical evaluation of the STA LIATEST immunoturbidimetric D-dimer assay for the diagnosis of disseminated intravascular coagulation. Am J Clin Pathol. 2004;122:178-84. (Pubitemid 38971349)
5. Wada H, Sase T, Matsumoto T, Kushiya F, Sakakura M, Mori Y, Nishikawa M, Ohnishi K, Nakatani K, Gabazza EC, Shiku H, Nobori T. Increased soluble fibrin in plasma from disseminated intravascular coagulation. Clin Appl Thromb Haemost. 2003;9:233-40. (Pubitemid 37070132)
6. Heit JA, Silverstein MD, Mohr DN, Petterson TM, Lohse CM, O'Fallon WM, Melton LJ 3rd. The epidemiology of venous thromboembolism in the community. Thromb Haemost. 2001;86:452-63. (Pubitemid 32663974)
7. Oger E. Incidence of venous thromboembolism: a communitybased study in Western France. EPI-GETBP Study Group. Groupe d'Etude de la Thrombose de Bretagne Occidentale. Thromb Haemost. 2000;83:657-60. (Pubitemid 30248509)
8. Courtney DM, Kline JA. Identification of prearrest clinical factors associated with outpatient fatal pulmonary embolism. Acad Emerg Med. 2001;8:1136-42. (Pubitemid 33108204)
9. Geerts WH, Heit JA, Clagett P, Pineo GF, Colwell CW, Anderson FA Jr, Wheeler HB. Prevention of venous thromboembolism. Chest. 2001;119:S132-75.
10. Piovella F, Wang CJ, Lu H, Lee K, Lee LH, Lee WC, Turpie AG, Gallus AS, Planès A, Passera R, AIDA investigators. Deep-vein thrombosis rates after major orthopedic surgery in Asia. An epidemiological study based on postoperative screening with centrally adjudicated bilateral venography. J Thromb Haemost. 2005;3:2664-70. (Pubitemid 41819793)
11. Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, Ray JG. Prevention of venous thromboembolism: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest. 2004;126:338S-400S. (Pubitemid 39302602)
12. Leclerc JR, Gent M, Hirsh J, Geerts WH, Ginsberg JS. The incidence of symptomatic venous thromboembolism after enoxaparin prophylaxis in lower extremity arthroplasty: a cohort study of 1984 patients. Canadian Collaborative Group. Chest. 1998;114:115S-8S.
13. Colwell CW Jr, Collis DK, Paulson R, McCutchen JW, Bigler GT, Lutz S, Hardwick ME. Comparison of enoxaparin and warfarin for the prevention of venous thromboembolic disease after total hip arthroplasty: evaluation during hospitalization and three months after discharge. J Bone Joint Surg. 1999;81- A:932-40. (Pubitemid 29355002)
14. Heit JA, Elliott CG, Trowbridge AA, Morrey BF, Gent M, Hirsh J. Ardeparin sodium for extended out-of-hospital prophylaxis against venous thromboembolism after total hip or knee replacement: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2000;132:853-61. (Pubitemid 30346847)
15. Bauersachs RM. Fondaparinux: an update on new study results. Eur J Clin Invest. 2005;35:27-32. (Pubitemid 40343878)
16. Turpie AG, Gallus AS, Pentasaccharide Investigators. A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement. N Engl J Med. 2001;344:619-25. (Pubitemid 32183576)
17. Turpie AG, Bauer KA, Eriksson BI. PENTATHALON 2000 Study Steering Committee.: Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial. Lancet. 2002;359:1721-6. (Pubitemid 34607085)
18. Teien AN, Lie M. Evaluation of an amidolytic heparin assay method: increased sensitivity by adding purified antithrombin III. Thromb Res. 1977;10:399-410. (Pubitemid 8061566)
19. van Putten J, van de Ruit M, Beunis M, Hemker HC. Determination of low molecular weight heparin in clinical laboratory. Haemostasis. 1984;14:205-10. (Pubitemid 14141530)
20. Tsuji A, Wada H, Matsumoto T, Abe Y, Ota S, Yamada N, Sugiyama T, Sudo A, Onishi K, Nakatani K, Uchida A, Ito M, Suzuki K, Nobori T. Elevated levels of soluble fibrin in patients with venous thromboembolism. Int J Hematol. 2008;88:448-53.
21. Schellong SM, Schwarz T, Halbritter K, Beyer J, Siegert G, Oettler W, Schmidt B, Schroeder HE. Complete compression ultrasonography of the leg veins as a single test for the diagnosis of deep vein thrombosis. Thromb Haemost. 2003;89:228-34. (Pubitemid 36227272)
22. Hiippala S, Strid L, Wennerstrand M, Arvela V, Mäntylä S, Ylinen J, Niemelä H. Tranexamic acid (Cyklokapron) reduces perioperative blood loss associated with total knee arthroplasty. Br J Anaesth. 1995;74:534-7.
23. Benoni G, Fredin H. Fibrinolytic inhibition with tranexamic acid reduces blood loss and blood transfusion after knee arthroplasty: a prospective, randomised, double-blind study of 86 patients. J Bone Joint Surg Br. 1996;78:434-40. (Pubitemid 26158834)
24. Jansen AJ, Andreica S, Claeys M, D'Haese J, Camu F, Jochmans K. Use of tranexamic acid for an effective blood conservation strategy after total knee arthroplasty. Br J Anaesth. 1999;83:596-601. (Pubitemid 29458825)
25. Veien M, Sørensen JV, Madsen F, Juelsgaard P. Tranexamic acid given intraoperatively reduces blood loss after total knee replacement: a randomized, controlled study. Acta Anaesthesiol Scand. 2002;46:1206-11. (Pubitemid 35341889)
26. Good L, Peterson E, Lisander B. Tranexamic acid decreases external blood loss but not hidden blood loss in total knee replacement. Br J Anaesth. 2003;90:596-9. (Pubitemid 36592332)
27. MacGillivray RG, Tarabichi SB, Hawari MF, Raoof NT. Tranexamic acid to reduce blood loss after bilateral total knee arthroplasty: a prospective, randomized double blind study. J Arthroplasty. 2011;26:24-8.